Compare Novo Nordisk A/S (NVO) vs Philip Morris International Inc. (PM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Philip Morris International Inc. — how do they compare? Novo Nordisk A/S trades at $49.35 (market cap $220.53B), while Philip Morris International Inc. trades at $188.62 (market cap $300.37B). The key difference: Philip Morris International Inc. is the larger of the two by market cap, and Novo Nordisk A/S pays the higher dividend (3.63%). Which is the better fit depends on your goals.
| NVO | PM | |
|---|---|---|
Market Cap | $220.53B | $300.37B |
Sector | Health | Consumer Staples |
52-Week High | $71.70 | $192.98 |
52-Week Low | $35.29 | $144.33 |
Enterprise Value | $239.49B | $346.86B |
Dividend Yield | 3.63% | 3.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Philip Morris International (PM) trades at $192.98, up 1.65% today, near the analyst consensus price target of $194. The stock shows a bullish technical trend with strong moving average support. Fundamentally, the company reported robust 2025 results with revenue of $40.65 billion and net income of $11.35 billion, though recent news highlights a $500 million impairment charge and reduced profit guidance for 2026 due to cost pressures.
The outlook remains cautiously optimistic with 68% of analysts rating it a Buy, but investors face headwinds from currency volatility, rising illicit tobacco trade in Europe, and margin compression. The stock's valuation at a P/E of 27.13 appears full priced, requiring continued execution to justify further upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Philip Morris International Inc.
Philip Morris International is an international tobacco company with a product portfolio primarily consisting of cigarettes and reduced-risk products, including heat-not-burn, vapor and oral nicotine products, which are sold in markets outside the United States. The company diversified away from nicotine products with the acquisition of Vectura, a provider of innovative inhaled drug delivery solutions, in 2021.
Read more on PM →
